



Ventripoint
Diagnostics Ltd.

Putting the Heart into AI

Echocardiography with the Accuracy of cardiac MRI

April 2024

Forward Looking Statements

Diagnostics Disclaimer The information in this presentation may include forward-looking statements related to our future growth, trends in our industry, our financial and or operational results, and our financial or operational performance. Such forward-looking statements are predictive in nature, and may be based on current expectations, forecasts or assumptions involving risks and uncertainties that could cause actual outcomes and results to differ materially from the forward-looking statements themselves. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans”, or similar expressions, or may employ such future or conditional verbs as “may”, “will”, “should” or “would”, or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. For these statements, we claim the protection of the safe harbour for forward-looking statements contained in the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. The risks and uncertainties referred to above include, but are not limited to: variability of operating results among periods; inability to retain or grow our business due to execution problems resulting from significant headcount reductions, plant closures and product transfer associated with major restructuring activities; the effects of price competition and other business and competitive factors generally affecting the EMS industry; the challenges of effectively managing our operations during uncertain economic conditions; our dependence on a limited number of customers; our dependence on industries affected by rapid technological change; the challenge of responding to lower-than-expected customer demand; our ability to successfully manage our international operations; and delays in the delivery and/or general availability of various components used in the manufacturing process. These and other risks and uncertainties and factors are discussed in the Company’s various public filings at www.sedar.com and www.sec.gov, including our Form 20-F and subsequent reports on Form 6-K filed with the Securities and Exchange Commission. Except as required by applicable law, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



About Ventripoint

Ventripoint is a Toronto-based public company (TSXV: VPT OTCQB: VPTDF) pioneering the application of Artificial Intelligence (AI) to echocardiography and whole-heart imaging

- Our VMS+ system is a fast and affordable ultrasound-based alternative to cardiac MRI (cMRI) that provides cardiologists greater confidence in the management of their patients
- VMS+ has been adopted by leading centres in the United States, Europe, the UK and Canada
- Over 60 studies demonstrate equivalent accuracy to cMRI
- Our sales strategy combines direct sales and distributors
- We are securing capital to advance the company into its growth phase



Current Situation

- Cardiac MRI (cMRI) is regarded as the gold standard for advanced or complex heart conditions, but is a complex and expensive modality
- Relatively small installed base of MRI systems and growing demands on healthcare systems creates challenges to access in some areas
- cMRI often not practical for young patients due to length of procedure, noise, claustrophobia plus use of sedation and contrast media in some cases
- Cardiac ultrasound (echo) is more accessible but dependent on operator ability and can generate inconsistent, unreliable measurements particularly for the RV
- Emerging technologies such as 3D Echo still do not answer the clinical challenges that consider the skill of the clinician, differences in patient anatomy across disease states and all physiology types



Ventripoint VMS+

- Built using a proprietary AI-based approach named Knowledge Based Reconstruction (KBR) that renders standard 2D echocardiograms into 3D volumetric images that provides cMRI-equivalent volumetric data to clinicians
- Faster, less expensive, more patient-friendly approach that can be used at the point-of-care and is less dependent on operator ability
- Enables more timely and responsive approach to managing cardiac health
- Approved product with initial placements in the US, EU, UK and Canada



SickKids

D|I|ZC DEUTSCHES HERZZENTRUM
DER CHARITÉ

THE UNIVERSITY OF TEXAS
MD Anderson
Cancer Center



Knowledge-based Reconstruction

VMS+ built using AI and machine learning techniques

- Utilizing proprietary algorithms, we synthesized the data from a proprietary cardiac MRI image catalogue to ensure accurate calculations for clinical confidence
- The KBR catalogue covers a wide array of clinical conditions and cardiac shapes
- VMS+ interfaces with all major brands of echocardiography systems



Our VMS+ Solutions



VMS+ V3.2 for 2D Echo takes 2D echocardiograms from any ultrasound machine and provides 3D cardiac measurements with accuracy equivalent to cardiac MRI

VMS+ Software for 3D Echo and MRI is a workstation solution that creates a 3D model of all 4 chambers of the heart with the use of any commercially available 3D echo or MRI images and generates reproducible and accurate volumetric measurements and ejection fractions



Whole heart analysis

All four heart chambers



Complex shapes

Provides MRI-equivalent results for Right Ventricle



Equivalency to cMRI

Eliminates need for cMRI to calculate volume and ejection fractions



Market Opportunity

- Congenital Heart Defects
 - Leading cause of death of children from non-communicable diseases
 - Estimated 13.3 million patients worldwide
 - 1 million children + 1.4 million adults in the U.S
- Up to one-third of chemotherapy patients experience cardiotoxic effects
 - VMS+ addresses current inability to accurately assess right ventricle ejection fractions using echo
- Pathologies related to the right ventricle such as Pulmonary Arterial Hypertension (PAH)



Paediatric Care

- No pre-scan dietary restrictions
- No sedation required (IV or oral)
- Approximately 5 minutes of total scan time vs 30 - 60 mins for MRI
- Patient able to move during the procedure
- No risks for patient during the procedure
- Patient can be accompanied by an adult



Adult Care

- Less costly in terms of the time required for the patient and the service provider
- Approximately 5 minutes of total scan time vs 3—60 mins for MRI
- Less costly to payors
- Elimination of MRI constraints for patients
- Improves quality of echo metrics to approximate that of MRI



\$2B Market Potential

- Calculated based on disease incidence/prevalence, medical guidelines for care and average utilization of ultrasound systems and VMS+ ASP of \$50,000 USD per system
- 7.1 million echocardiograms performed yearly in the U.S.

Imputed Number of Ultrasound Systems by Indication				
Application	USA	Europe/UK	Canada	Total
Congenital Heart Defects	4,000	6,000	400	10,400
Pulmonary Hypertension	2,000	3,000	200	5,200
Oncology	10,000	15,000	1,000	26,000
Total	16,000	24,000	1,600	41,600



Management Team

Hugh MacNaught, President and CEO

Fortune 100 trained executive with thirty years experience in the innovation, development, financing, and commercialisation of medical and life science technologies. His familiarity with research translation and technology development within early stage companies includes several years as a venture capitalist and founding, leading and financing technology ventures.

Bart Hendriks, Strategic Partnerships Executive

A seasoned professional in the MedTech artificial intelligence field, Bart brings a wealth of experience from his tenure in various leadership capacities, including CEO and Founder of innovative ventures in medical technology, diagnostics, and AI-driven clinical applications.

Scott Hammerling, Strategic Sales Leader

Experienced sales leader with a demonstrated history within the medical device industry. Experience includes ultrasound, radiology, software and capital equipment



Board of Directors

George Adams, Ph.D., ICD.D, Chairman

Dr. Adams is a serial entrepreneur and has held research and executive roles within Boston Scientific, Pfizer, and Corvita. He has raised more than \$100 million and achieved successful exits.

Hugh MacNaught, President & CEO, Director

Robert Hodgkinson, Director

Mr. Hodgkinson has over 40 years of experience in public capital markets. He has raised \$150M of capital, is an experienced corporate director, senior executive and adviser.

Fiona Fitzgerald, Director

Ms. Fitzgerald is National Zone Leader for Cytiva Life Science, formerly part of GE. Ms. Fitzgerald chaired NSERC's CREATE program, and holds board memberships in CIMTEC, MDCC, and is on the Advisory Board for the Centre of Bioengineering and Biotechnology in Waterloo University.

Randy Aucoin, Director

Mr. AuCoin is President and CEO of Exact Imaging, the world leader in high-frequency ultrasound for early detection of prostate cancer. He has raised over \$60 million of venture capital and has extensive experience in finance, sales and marketing, and operations.



Current Financing

- Private placement of unsecured Convertible Debentures
- \$1,000 per debenture
- Conversion price of \$0.25 per Common Share
- 10% interest per annum, payable semi-annually in arrears
 - Up to 60% payable by issuance of Common Shares
- 36 month maturity
- Automatic conversion if VWAP for 5 consecutive trading days exceeds 100% of the conversion price
 - If automatic conversion occurs holders receive 50% warrant coverage at exercise price of \$0.70



Use of Proceeds

- ▶ Marketing, Sales and Business Development
- ▶ Scale Operations and Manufacturing
- ▶ Accelerate Product Roadmap
- ▶ Operating Capital



Capitalization

Shares Outstanding	156.8M
Options @\$0.25	9.7M
Warrants @\$0.68	15.6M
Fully Diluted	182.0M

Recent Share Price	CDN\$.230
52-Week Range	CDN\$.12-.36
Market Cap	CDN\$36M
Debt	none
Liquidity (2023)	300k shares/day

TSXV: VPT OTCQB: VPTDF





Ventripoint
Diagnostics Ltd.

Putting the Heart into AI

For more information please contact:

Jonathan Robinson
Partner

Oak Hill Financial
Tel: +1 416 669 1001

E-mail : jrobinson@oakhillfinancial.com